Enveda Therapeutics, Inc. — Form D
Enveda Therapeutics, Inc. of Boulder, CO, a company, filed a Form D exempt-offering notice with the SEC on 2023-03-07. The offering totals $62.5M, of which $62.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-03-07
- Form: D
- Accession: 0001821392-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $62.5M
- Amount sold: $62.5M
- Investors: 26
- Date of first sale: 2022-08-25
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-475101
Issuer
- Name: Enveda Therapeutics, Inc.
- CIK: 0001821392
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 1880 S Flatiron Ct. Ste. K, Boulder, CO, 80301
- Phone: 415-323-5252
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Bruce Beutel | Director | Boulder, CO |
| Viswa Colluru | Director | Boulder, CO |
| Zavain Dar | Director | San Francisco, CA |
| Rohit Sharma | Director | Longmont, CO |
| Shaquille Vayda | Director | Boulder, CO |
| Viswa Colluru | Executive Officer | Boulder, CO |
| Daniel Wee | Executive Officer | Boulder, CO |
Other filings by this issuer (1)
More